Blueprint Medicines: Q3 Earnings Insights

Shares of Blueprint Medicines BPMC were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share were up 678.24% year over year to $11.16, which beat the estimate of $7.72.

Revenue of $745,118,000 rose by 8053.17% year over year, which beat the estimate of $631,570,000.

Looking Ahead

Blueprint Medicines hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Oct 29, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/8kkmicit

Technicals

52-week high: $106.50

Company's 52-week low was at $43.29

Price action over last quarter: Up 42.98%

Company Description

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.